FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for NUBEQA (darolutamide) filed by Bayer, updating the labeling for its use in nonmetastatic castration-resistant pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmetastatic Castration-resistant Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

SUPPL AP for NUBEQA (DAROLUTAMIDE)